Teva meets profit expectations but misses on revenue
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA TASE: TEVA) now documented $3.7 billion earnings for the 1st quarter of 2022, down 8% from the corresponding quarter of 2021, and somewhat down below the analysts’ consensus of $3.75 billion. Non-GAAP earnings per share was $.55, meeting the analysts’ forecast.

Teva reduce its 2022 revenue forecast from $15.6-16.2 billion to $15.4-16 billion and its Copaxone gross sales forecast from $850 million to $750 million.




Linked Content articles













In response, Teva’s share price tag is down 2.58% in premarket investing on the NYSE.

Teva president and CEO Kare Schultz stated, We are delighted to carry on resolving opioid-relevant litigations with the latest settlements in Florida and Rhode Island such as the provision of lifesaving opioid treatment plans and restoration medications for those people who require them.”

He ongoing: “Although easing of Covid-19 similar limitations has led to favourable momentum in our European company, we are viewing fluctuations of overseas exchange fees, and have thus lowered our 2022 income outlook, although reaffirming our earnings and money flow assistance.”

Revealed by Globes, Israel organization news – en.globes.co.il – on Might 3, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.


